Allurion Technologies Holdings Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allurion Technologies reports Q3 revenue decline, eyes FDA approval

Allurion Technologies Holdings Inc faced challenges in Q3 due to the suspension of the Allurion Balloon in France and macro headwinds, leading to a decrease in revenue. However, the company highlighted strengths in the Middle East and Latin America, with plans to double revenues by year-end and pursue FDA approval for the Allurion Balloon.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update.

Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023.

Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. “I believe the brisk enrollment in the AUDACITY trial reflects the.

Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced acceptance of five abstracts that will be presented at Obesity Week 2023, the annual meeting of The Obesity Society to be held in Dallas, Texas from October 14-17. Presentations will include new findings on the use of artificial intelligence (AI) and machine learning to support provider decision-making and streamline workflow, automate coaching and follow-up, and asse.

Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced its participation in the 4th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023. The IBC event, entitled ‘Managing Obesity and Diabetes: From the Laboratory to the Clinic to the Operating Room to the World', will bring together many of the world's most distinguished weight-loss experts. Brazilian bar.

Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, has today unveiled Coach Iris, a new generative AI-powered health coach designed to enhance outcomes within the Allurion Program and maximize clinic efficiency. Built in close collaboration with leading global weight-management professionals and Allurion's behavioral scientists, Coach Iris is intended to instantly expand the care team by providing always-on support, education, and mo.

Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach

NATICK, Mass.--(BUSINESS WIRE)--Allurion (NYSE: ALUR), a company dedicated to ending obesity, today announced the acceptance of nine scientific presentations at the upcoming 26th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). These presentations consist of four abstracts that will be presented as oral presentations, four abstracts that will be presented as posters, and one moderated presentation. IFSO takes place in Naples, Italy, from.

Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress

News for Allurion Technologies Holdings Inc Stock (ALUR)